18_CD
Operating_GER
and_CC
financial_JJ
review_NN
How_RB
we_FPP1
manage_VPRT
our_FPP1
business_NOMZ
:_:
finance_NN
and_PHC
risk_NN
We_FPP1
have_VPRT [PEAS]
put_VBN
in_PIN
place_NN
robust_JJ
systems_NN
to_TO
manage_VB
our_FPP1
financial_JJ
practices_NN
and_PHC
areas_NN
that_TSUB
put_VPRT
Acambis_NN
business_NOMZ
at_PIN
risk_NN
._.
Over_IN
the_DT
last_JJ
few_QUAN
years_NN
,_,
we_FPP1
have_VPRT [SPAU] [PEAS]
particularly_RB
focused_VBN
on_PIN
improving_VBG
our_FPP1
handling_GER
of_PIN
risks_NN
by_PIN
embedding_VBG
a_DT
risk_NN
management_NOMZ
framework_NN
into_PIN
our_FPP1
operations_NOMZ
._.
Financial_NN
systems_NN
The_DT
following_JJ
section_NOMZ
sets_VPRT
out_PIN
some_QUAN
of_PIN
exchange_NN
rate_NN
exposures_NN
,_,
given_VBN
our_FPP1
smallpox_NN
vaccine_NN
contract_NN
._.
Owing_VBG [PRESP]
to_PIN
the_DT
main_JJ
financial_JJ
parameters_NN
through_PIN
reporting_VBG [PUBV] [THATD]
currency_NN
is_VPRT
sterling_GER
._.
the_DT
timing_NN
of_PIN
certain_JJ
costs_NN
under_IN
that_DEMP
which_WDT
we_FPP1
manage_VPRT
our_FPP1
business_NOMZ
._.
We_FPP1
manage_VPRT
our_FPP1
cash_NN
in_PIN
money_NN
market_NN
contract_NN
,_,
some_QUAN
funds_NN
have_VPRT [PEAS]
been_VBN [PASS]
received_VBN
funds_NN
with_PIN
the_DT
aid_NN
of_PIN
professional_JJ
money_NN
in_PIN
advance_NN
of_PIN
costs_NN
having_VBG [WZPRES] [PEAS]
been_VBN [PASS]
incurred_VBN
CAPITAL_NN
STRUCTURE_NN
market_NN
managers_NN
._.
The_DT
Board_NN
regularly_RB
and_CC
,_,
as_CONJ
a_NULL
result_NULL
,_,
this_DEMP
will_PRMD
give_VB
rise_VB
to_PIN
a_DT
At_PIN
the_DT
end_NN
of_PIN
2003_CD
,_,
Acambis_NN
had_VBD
reviews_VPRT
the_DT
performance_NN
of_PIN
those_DEMO
funds_NN
large_JJ
negative_JJ
cash_NN
movement_NOMZ
in_PIN
2004_CD
._.
approximately_RB
125m_JJ
invested_VBN
in_PIN
cash_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
they_TPP3
achieve_VB
competitive_JJ
rates_NN
and_CC
short-term_JJ
investments_NOMZ
._.
Our_FPP1
treasury_NN
policy_NN
ensures_VPRT [SUAV] [PRIV]
CURRENT_NN
LIQUIDITY_NOMZ
that_DEMO
through_PIN
the_DT
course_NN
of_PIN
2004_CD
this_DEMO
that_DEMO
our_FPP1
capital_NN
is_VPRT [BEMA]
not_XX0
at_PIN
risk_NN
._.
During_PIN
As_IN
referred_VBN
to_PIN
within_PIN
Capital_NN
structure_NN
,_,
will_PRMD
reduce_VB
to_PIN
nearer_IN
100m_CD
as_IN
a_DT
large_JJ
2003_CD
,_,
we_FPP1
hedged_VBD
certain_JJ
foreign_JJ
we_FPP1
currently_RB
have_VPRT
a_DT
lease-financing_JJ
working_GER
capital_NN
movement_NOMZ
unwinds_VPRT
._.
exchange_NN
exposures_NN
but_CC
did_VBD
not_XX0
have_VB
facility_NOMZ
in_PIN
relation_NOMZ
to_PIN
the_DT
reactivation_NOMZ
Given_VBN
our_FPP1
healthy_JJ
cash_NN
balance_NN
we_FPP1
have_VPRT
any_QUAN
instruments_NOMZ
outstanding_JJ
at_PIN
the_DT
of_PIN
our_FPP1
manufacturing_GER
facility_NOMZ
._.
At_PIN
the_DT
not_XX0
had_VBD
to_TO
increase_VB
our_FPP1
debt_NN
profile_NN
end_NN
of_PIN
the_DT
year_NN
._.
We_FPP1
manage_VPRT
this_DEMO
area_NN
end_NN
of_PIN
2003_CD
,_,
$_$
22.5_CD
m_NN
c._NN
12.6_CD
m_NN [BEMA]
of_PIN
in_PIN
the_DT
last_JJ
couple_NN
of_PIN
years_NN
._.
on_PIN
an_DT
ongoing_JJ
basis_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
that_DEMP
,_,
a_DT
potential_JJ
$_$
40m_CD
had_VBD [PEAS]
been_VBN [PASS]
drawn_VBN
At_PIN
31_CD
December_NN
2003_CD
,_,
we_FPP1
had_VBD
$_$
29.5_CD
m_NN
where_RB
possible_JJ
,_,
potential_JJ
areas_NN
of_PIN
risk_NN
down_IN
from_PIN
the_DT
facility_NOMZ
._.
We_FPP1
do_VPRT
not_XX0
16.5_CD
m_NN [BEMA]
of_PIN
US_FPP1
dollar-denominated_JJ
debt_NN
are_VPRT [SPAU] [PASS]
appropriately_RB
mitigated_VBN
._.
currently_RB
envisage_NN
utilising_VBG [WZPRES]
the_DT
on_PIN
our_FPP1
balance_NN
sheet_NN
,_,
comprising_VBG [PRESP]
Of_PIN
the_DT
$_$
29.5_CD
m_NN [BEMA]
16.5_CD
m_NN
US_FPP1
dollarundrawn_JJ
amount_NN
._.
a_DT
lease-financing_JJ
facility_NOMZ
for_PIN
the_DT
denominated_VBN
debt_NN
as_IN
referred_VBN
to_PIN
within_PIN
reactivation_NOMZ
of_PIN
our_FPP1
manufacturing_GER
Capital_NN
Structure_NN
,_,
the_DT
interest_NN
rate_NN
INTERNAL_JJ
SOURCES_NN
OF_PIN
LIQUIDITY_NOMZ
plant_NN
and_CC
an_DT
overdraft_NN
facility_NOMZ
for_PIN
the_DT
payable_JJ
on_PIN
the_DT
$_$
22.5_CD
m_NN
finance_NN
lease_NN
is_VPRT [BEMA]
The_DT
Group_NN
has_VPRT
a_DT
number_NN
of_PIN
interARILVAX_NN
program_NN
._.
Under_IN
the_DT
fixed_VBN
at_PIN
6.25_CD
%_NN
per_PIN
annum_NN
for_PIN
the_DT
life_NN
company_NN
agreements_NOMZ
between_PIN
its_PIT
current_JJ
terms_NN
of_PIN
these_DEMO
arrangements_NOMZ
,_,
of_PIN
the_DT
lease_NN
:_:
and_ANDC
the_DT
$_$
7m_CD
ARILVAX_NN
companies_NN
that_TSUB
have_VPRT
historically_RB
both_DT
these_DEMO
debts_NN
will_PRMD
be_VB [PASS]
repaid_VBN
within_PIN
overdraft_NN
facility_NOMZ
is_VPRT [PASS]
charged_VBN
at_PIN
0.35_CD
%_NN
been_VBN [PASS]
put_VBN
in_PIN
place_NN
to_TO
secure_VB
the_DT
the_DT
next_JJ
three_CD
years_NN
._.
per_PIN
annum_NN
above_PLACE
the_DT
bank_NN
base_NN
rate_NN
long-term_JJ
funding_GER
requirements_NOMZ
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
cash_NN
will_PRMD
be_VB [BEMA]
for_PIN
US_FPP1
dollars_NN
._.
of_PIN
each_QUAN
of_PIN
those_DEMO
companies_NN
._.
sufficient_JJ
for_PIN
the_DT
operational_JJ
needs_NN
of_PIN
our_FPP1
business_NOMZ
for_PIN
the_DT
medium-term_JJ
._.
CASH_NN
FLOWS_NN
GOING_VBG [WZPRES]
CONCERN_NN
STATEMENT_NOMZ
During_PIN
2003_CD
,_,
the_DT
net_JJ
cash_NN
and_CC
liquid_JJ
The_DT
Directors_NN
have_VPRT
a_DT
reasonable_JJ
TREASURY_NN
POLICY_NN
resources_NN
inflow_NN
for_PIN
the_DT
Group_NN
was_VBD
expectation_NOMZ
that_TOBJ
the_DT
Company_NN
and_CC
The_DT
Group_NN
holds_VPRT [PRIV]
its_PIT
cash_NN
in_PIN
a_DT
mix_NN
of_PIN
113.4_CD
m_NN
,_,
with_PIN
119.1_CD
m_NN [PASS]
derived_VBN [WZPAST]
from_PIN
the_DT
Group_NN
have_VPRT
adequate_JJ
resources_NN
sterling_GER
,_,
US_FPP1
dollars_NN
and_PHC
euros_NN
._.
Cash_NN
is_VPRT
operating_VBG
activities_NOMZ
and_CC
a_DT
net_JJ
cash_NN
and_CC
to_TO
continue_VB
their_TPP3
operations_NOMZ
for_PIN
the_DT
invested_VBN
in_PIN
this_DEMO
range_NN
of_PIN
currencies_NN
such_JJ
liquid_JJ
resources_NN
outflow_NN
of_PIN
5.7_CD
m_NN [BEMA]
from_PIN
foreseeable_JJ
future_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
that_DEMP
working_VBG
capital_NN
requirements_NOMZ
for_PIN
investment_NOMZ
and_PHC
financing_GER
activities_NOMZ
._.
Directors_NN
have_VPRT [PEAS]
adopted_VBN
the_DT
going_VBG
the_DT
components_NN
of_PIN
the_DT
Group_NN
can_POMD
be_VB [BEMA]
By_PIN
the_DT
end_NN
of_PIN
2003_CD
,_,
we_FPP1
had_VBD [PEAS]
received_VBN
concern_NN
basis_NN
in_PIN
preparing_VBG
the_DT
met_VBN
._.
Where_RB
appropriate_JJ
,_,
it_PIT
is_VPRT [BEMA]
our_FPP1
policy_NN
the_DT
vast_JJ
majority_NOMZ
of_PIN
cash_NN
due_JJ
from_PIN
our_FPP1
financial_JJ
statements_NOMZ
._.
to_TO
invest_VB
surplus_NN
funds_NN
in_PIN
sterling_GER
,_,
largest_JJ
customer_NN
,_,
the_DT
US_FPP1
Centers_NN
for_PIN
which_WDT [PIRE]
currently_RB
attracts_VPRT
a_DT
higher_JJ
Disease_NN
Control_NN
and_PHC
Prevention_NOMZ
CDC_NN
,_,
interest_NN
rate_NN
and_PHC
mitigates_NN
certain_JJ
in_PIN
respect_NN
of_PIN
our_FPP1
$_$
428m_CD
c._NN
240m_JJ
19_CD
Risk_NN
management_NOMZ
Over_IN
the_DT
last_JJ
few_QUAN
years_NN
we_FPP1
have_VPRT
As_IN
our_FPP1
business_NOMZ
has_VPRT [PEAS]
matured_VBN
over_IN
Section_NOMZ
404_CD
Attestation_NOMZ
Management_NOMZ
given_VBN
priority_NOMZ
to_TO
embedding_VBG
a_DT
risk_NN
the_DT
last_JJ
few_QUAN
years_NN
from_PIN
a_DT
loss-making_JJ
Assessment_NOMZ
of_PIN
Internal_NN
Control_NN
,_,
with_PIN
management_NOMZ
framework_NN
into_PIN
the_DT
R&D_NN
organization_NOMZ
to_PIN
a_DT
fully_AMP
integrated_VBN
Auditor_NN
Attestation_NOMZ
of_PIN
the_DT
Sarbanes_NN
operations_NOMZ
of_PIN
our_FPP1
business_NOMZ
._.
All_QUAN
profitable_JJ
biotechnology_NN
company_NN
,_,
Oxley_NN
Act_NN
of_PIN
2002_CD
in_PIN
the_DT
US_FPP1
._.
managers_NN
are_VPRT [BEMA]
encouraged_JJ
proactively_RB
this_DEMP
has_VPRT [PEAS]
brought_VBN
with_PIN
it_PIT
new_JJ
risks_NN
for_PIN
We_FPP1
do_VPRT
not_XX0
currently_RB
have_VPRT
a_DT
formal_JJ
to_TO
manage_VB
risk_NN
within_PIN
their_TPP3
own_JJ
the_DT
business_NOMZ
to_TO
manage_VB
._.
The_DT
structure_NN
internal_JJ
audit_NN
function_NOMZ
._.
However_CONJ
,_,
the_DT
area_NN
and_CC
to_TO
identify_VB
potential_JJ
areas_NN
of_PIN
we_FPP1
have_VPRT [PEAS]
developed_VBN
to_TO
manage_VB
risk_NN
Audit_NN
Committee_NN
regularly_RB
reviews_VPRT
exposure_NN
._.
The_DT
Executive_NN
Directors_NN
are_VPRT
is_VPRT [BEMA]
both_DT
robust_JJ
and_PHC
flexible_JJ
,_,
enabling_VBG [PRESP]
this_DEMO
requirement_NOMZ
and_CC
will_PRMD
do_VB
so_RB
again_TIME
responsible_JJ
for_PIN
reporting_VBG [PUBV]
to_PIN
the_DT
Board_NN
us_FPP1
to_TO
add_VB [PUBV]
in_PIN
new_JJ
components_NN
as_IN
our_FPP1
during_PIN
2004_CD
._.
via_PIN
the_DT
Audit_NN
Committee_NN
on_PIN
our_FPP1
risk_NN
business_NOMZ
changes_NN
._.
We_FPP1
also_RB
engage_VPRT
a_DT
number_NN
of_PIN
external_JJ
management_NOMZ
program_NN
._.
Early_TIME
in_PIN
2004_CD
,_,
we_FPP1
assigned_VBD
a_DT
parties_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
we_FPP1
are_VPRT
covering_VBG
all_QUAN
We_FPP1
are_VPRT [BEMA]
conscious_PRED
that_THAC
managing_VBG
dedicated_JJ
resource_NN
to_TO
assess_VB
and_PHC
test_VB
risk_NN
areas_NN
,_,
from_PIN
consultants_NN
to_PIN
auditors_NN
,_,
risk_NN
is_VPRT [BEMA]
an_DT
ongoing_JJ
process_NN
and_CC
we_FPP1
our_FPP1
internal_JJ
controls_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
we_FPP1
from_PIN
legal_JJ
advisers_NN
to_PIN
insurers_NN
._.
continue_VB
to_TO
build_VB
on_PIN
it_PIT
each_QUAN
year_NN
._.
comply_VB
as_IN
a_DT
foreign_JJ
registrant_NN
with_PIN
This_DEMP
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
some_QUAN
of_PIN
the_DT
main_JJ
risks_NN
to_PIN
which_WDT [PIRE]
Acambis_NN
is_VPRT [SPAU] [PASS]
currently_RB
exposed_VBN
:_:
having_VBG [PRESP]
only_DWNT
one_CD
main_JJ
revenue_NN
stream_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
generated_VBN
by_PIN
sales_NN
of_PIN
our_FPP1
investigational_JJ
smallpox_NN
vaccine_NN
to_PIN
governments_NOMZ
:_:
the_DT
lack_NN
of_PIN
a_DT
substantial_JJ
recurring_VBG
revenue_NN
stream_NN
:_:
the_DT
ever-increasing_JJ
requirements_NOMZ
of_PIN
the_DT
regulatory_JJ
process_NN
in_PIN
respect_NN
of_PIN
our_FPP1
seven_CD
products_NN
in_PIN
clinical_JJ
development_NOMZ
:_:
and_ANDC
potential_JJ
failure_NN
of_PIN
a_DT
product_NN
in_PIN
clinical_JJ
development_NOMZ
._.
WE_FPP1
VIEW_NN
THE_DT
RISKS_NN
TO_PIN
ACAMBIS_NN
IN_PIN
THE_DT
FOLLOWING_VBG
WAY_NN
:_:
Involving_VBG
external_JJ
parties_NN
in_PIN
the_DT
Risks_NN
common_JJ
to_PIN
all_QUAN
businesses_NOMZ
process_NN
brings_VPRT
impartiality_NOMZ
and_CC
e._FW
g._FW
GOVERNMENT_NOMZ
LEGISLATION_NOMZ
objectivity_NOMZ
to_PIN
the_DT
process_NN
,_,
thereby_RB
ultimately_RB
serving_VBG
to_TO
manage_VB
the_DT
business_NOMZ
better_RB
for_PIN
all_QUAN
stakeholders_NN
._.
Risks_NN
common_JJ
to_PIN
biotech_JJ
businesses_NOMZ
We_FPP1
provide_VPRT
further_JJ
information_NOMZ
e._FW
g._FW
PRODUCT_NN
FAILURE_NN
on_PIN
this_DEMO
risk_NN
management_NOMZ
process_NN
,_,
general_JJ
risks_NN
to_PIN
which_WDT [PIRE]
all_QUAN
businesses_NOMZ
are_VPRT [PASS]
exposed_VBN
and_CC
a_DT
summary_NN
of_PIN
some_QUAN
Risks_NN
common_JJ
to_PIN
of_PIN
the_DT
more_EMPH
specific_JJ
risks_NN
to_PIN
which_WDT [PIRE]
vaccine_NN
companies_NN
Acambis_NN
is_VPRT [PASS]
exposed_VBN
on_PIN
pages_NN
28_CD
to_PIN
33_CD
._.
e._FW
g._FW
REGULATORY_NN
ISSUES_NN
Risks_NN
specific_JJ
to_PIN
Acambis_NN
e._FW
g._FW
LOSS_NN
OF_PIN
CERTAIN_NN
EMPLOYEES_NN
20_CD
Operating_GER
and_CC
financial_JJ
review_NN
How_RB
we_FPP1
manage_VPRT
our_FPP1
business_NOMZ
:_:
CSR_NN
We_FPP1
recognize_VPRT [PRIV]
that_THVC
there_EX
is_VPRT
an_DT
increasing_VBG
interest_NN
in_PIN
the_DT
Corporate_JJ
Social_NN
Responsibility_NOMZ
CSR_NN
activities_NOMZ
of_PIN
companies_NN
such_JJ
as_IN
Acambis_NN
._.
During_PIN
the_DT
last_JJ
year_NN
,_,
we_FPP1
have_VPRT [PEAS]
been_VBN
analyzing_VBG
the_DT
diverse_JJ
information_NOMZ
requirements_NOMZ
of_PIN
our_FPP1
various_JJ
stakeholders_NN
in_PIN
order_NN
to_TO
identify_VB
what_WP
they_TPP3
most_EMPH
want_VPRT
to_TO
know_VB [PRIV]
about_IN
how_RB
we_FPP1
run_VPRT
our_FPP1
business_NOMZ
._.
From_PIN
this_DEMO
analysis_NN
,_,
we_FPP1
have_VPRT [PEAS]
identified_VBN
five_CD
key_JJ
areas_NN
:_:
employees_NN
,_,
health_NN
and_PHC
safety_NN
,_,
environmental_JJ
impact_NN
,_,
community_NOMZ
involvement_NOMZ
and_PHC
issues_NN
specific_JJ
to_PIN
our_FPP1
industry_NN
._.
We_FPP1
are_VPRT
undertaking_VBG
an_DT
audit_NN
of_PIN
our_FPP1
activities_NOMZ
which_WDT [WHOBJ]
,_,
in_CONJ
addition_NULL
to_PIN
these_DEMO
key_JJ
areas_NN
,_,
is_VPRT
looking_VBG
at_PIN
relationships_NN
with_PIN
customers_NN
and_PHC
suppliers_NN
._.
We_FPP1
plan_VPRT
to_TO
publish_VB
the_DT
information_NOMZ
we_FPP1
compile_VPRT
on_PIN
these_DEMO
activities_NOMZ
on_PIN
our_FPP1
website_JJ
www_NN
._.
Here_RB
,_,
we_FPP1
are_VPRT
publishing_VBG
an_DT
overview_NN
of_PIN
our_FPP1
activities_NOMZ
in_PIN
these_DEMO
key_JJ
areas_NN
._.
DEVELOPING_VBG
VACCINES_NN
TO_TO
SAVE_VB
LIVES_NN
The_DT
most_EMPH
important_JJ
aspect_NN
of_PIN
Acambis_NN
contribution_NOMZ
to_PIN
society_NN
is_VPRT [BEMA]
the_DT
work_NN
we_FPP1
do_VPRT [PROD]
day_NN
in_PIN [STPR]
,_,
day_NN
out_PIN
:_:
developing_VBG
new_JJ
vaccines_NN
against_PIN
infectious_JJ
diseases_NN
._.
The_DT
disease_NN
areas_NN
we_FPP1
are_VPRT
targeting_VBG
affect_VB
the_DT
lives_NN
of_PIN
tens_NN
of_PIN
millions_NN
of_PIN
people_NN
every_QUAN
year_NN
._.
For_CONJ
instance_NULL
,_,
there_EX
are_VPRT
an_DT
estimated_VBN [PRIV]
50_CD
million_CD
cases_NN
of_PIN
dengue_NN
infection_NOMZ
every_QUAN
year_NN
,_,
of_PIN
which_WDT [PIRE]
500,000_CD
develop_VB
into_PIN
the_DT
more_EMPH
severe_JJ
dengue_NN
hemorrhagic_JJ
fever_NN
,_,
which_WDT [SERE]
has_VPRT
an_DT
average_JJ
20_CD
%_NN
fatality_NOMZ
rate_NN
._.
There_EX
is_VPRT
no_SYNE
licensed_JJ
vaccine_NN
against_PIN
dengue_NN
._.
Our_FPP1
investigational_JJ
vaccine_NN
is_VPRT
undergoing_VBG
clinical_JJ
testing_GER
._.
Even_RB
in_PIN
the_DT
case_NN
of_PIN
our_FPP1
smallpox_NN
vaccine_NN
,_,
where_RB
the_DT
virus_NN
is_VPRT
no_RB
longer_RB
WORLDWIDE_NN
DISTRIBUTION_NOMZ
OF_PIN
DENGUE_NN
SOURCE_NN
:_:
CDC_NN
circulating_VBG [WZPRES]
,_,
we_FPP1
are_VPRT
playing_VBG
an_DT
important_JJ
part_NN
in_PIN
worldwide_JJ
preparations_NOMZ
to_TO
defend_VB
AREAS_NN
INFESTED_NN
WITH_PIN
DENGUE-TRANSMITTING_GER
MOSQUITO_NN
against_PIN
a_DT
potentially_RB
catastrophic_JJ
AREAS_NN
WITH_PIN
DENGUE-TRANSMITTING_GER
MOSQUITO_NN
AND_PHC
DENGUE_NN
EPIDEMIC_NN
ACTIVITY_NOMZ
bioterrorist_NN
event_NN
._.
21_CD
OUR_FPP1
EMPLOYEES_NN
ENVIRONMENTAL_JJ
MANAGEMENT_NOMZ
INDUSTRY_NN
ISSUES_NN
Much_QUAN
of_PIN
our_FPP1
value_NN
and_PHC
potential_NN
for_PIN
The_DT
biotechnology_NN
industry_NN
is_VPRT [BEMA]
generally_RB
In_PIN
our_FPP1
industry_NN
,_,
there_EX
are_VPRT
a_DT
number_NN
success_NN
sits_VPRT
with_PIN
our_FPP1
employees_NN
and_CC
recognized_VBN [PRIV]
as_IN
having_VBG
a_DT
relatively_RB
low_JJ
of_PIN
ethical_JJ
issues_NN
that_TOBJ
a_DT
company_NN
such_JJ
the_DT
intellectual_JJ
capital_NN
they_TPP3
represent_VPRT
impact_NN
on_PIN
the_DT
environment_NOMZ
in_PIN
terms_NN
of_PIN
as_IN
Acambis_NN
needs_VPRT
to_TO
address_VB
._.
through_PIN
their_TPP3
experience_NN
and_PHC
expertise_NN
._.
emissions_NN
and_PHC
use_NN
of_PIN
materials_NN
._.
A_DT
waste_NN
The_DT
most_EMPH
high_JJ
profile_NN
of_PIN
these_DEMP
is_VPRT [BEMA]
We_FPP1
believe_VPRT [PRIV]
in_PIN
rewarding_VBG
them_TPP3
production_NOMZ
survey_NN
conducted_VBN [WZPAST]
at_PIN
one_CD
of_PIN
the_DT
use_NN
of_PIN
animals_NN
to_PIN
test_NN
products_NN
appropriately_RB
for_PIN
the_DT
contribution_NOMZ
they_TPP3
our_FPP1
sites_NN
a_DT
few_QUAN
years_NN
ago_IN
confirmed_VBD [PUBV]
this_DEMO
before_IN
they_TPP3
advance_VPRT
to_PIN
clinical_JJ
trials_NN
make_VPRT
to_PIN
our_FPP1
success_NN
,_,
both_DT
through_PIN
their_TPP3
view_NN
._.
We_FPP1
are_VPRT
continuing_VBG
to_TO
assess_VB
our_FPP1
in_PIN
humans_NN
._.
This_DEMO
type_NN
of_PIN
testing_GER
is_VPRT [BEMA]
remuneration_PRED
and_CC
through_PIN
an_DT
annual_JJ
activities_NOMZ
in_PIN
this_DEMO
area_NN
and_CC
to_TO
identify_VB
required_VBN [SUAV]
by_PIN
law_NN
in_PIN
our_FPP1
home_NN
territories_NN
bonus_NN
scheme_NN
that_DEMP
is_VPRT [PASS]
linked_VBN
to_PIN
personal_JJ
and_CC
act_NN
upon_PIN
ways_NN
to_TO
reduce_VB
what_WP
of_PIN
the_DT
UK_NN
and_CC
the_DT
US_FPP1
and_CC
is_VPRT [PASS]
undertaken_VBN
and_CC
company_NN
performance_NN
._.
within_PIN
a_DT
very_AMP
strict_JJ
and_CC
well_RB
regulated_VBN
We_FPP1
aim_VPRT
to_TO
involve_VB
our_FPP1
employees_NN
framework_NN
._.
We_FPP1
apply_VPRT
rigorous_JJ
standards_NN
closely_RB
in_PIN
the_DT
Groups_NN
progress_NN
through_PIN
COMMUNITY_NOMZ
INVOLVEMENT_NOMZ
to_PIN
any_QUAN
such_JJ
work_NN
,_,
including_VBG
oversight_NN
share_NN
ownership_NN
._.
All_QUAN
employees_NN
are_VPRT [BEMA]
Our_FPP1
community_NOMZ
activities_NOMZ
focus_VB
on_PIN
two_CD
by_PIN
internal_JJ
and_PHC
external_JJ
ethical_JJ
review_NN
awarded_VBN
share_NN
options_NOMZ
when_RB
they_TPP3
join_VPRT
key_JJ
areas_NN
:_:
supporting_VBG
employees_NN
efforts_NN
committees_NN
and_PHC
enforcement_NOMZ
of_PIN
the_DT
Acambis_NN
and_CC
at_PIN
other_JJ
times_NN
during_PIN
their_TPP3
to_TO
raise_VB
funds_NN
for_PIN
charity_NOMZ
:_:
and_ANDC
involvement_NOMZ
three_CD
Rs_NN
concept_NN
refine_VB
,_,
reduce_VB
,_,
employment_NOMZ
,_,
and_ANDC
they_TPP3
are_VPRT [SPAU] [PASS]
also_RB
given_VBN
with_PIN
organizations_NOMZ
or_CC
events_NN
related_VBN
replace_VB
._.
We_FPP1
have_VPRT [SPAU] [PEAS]
always_RB
sought_VBN
to_PIN
the_DT
opportunity_NOMZ
to_TO
participate_VB
in_PIN
share_NN
to_PIN
promotion_NOMZ
of_PIN
conduct_NN
such_JJ
work_NN
in_PIN
countries_NN
such_JJ
as_IN
save_IN
schemes_NN
._.
the_DT
UK_NN
and_CC
the_DT
US_FPP1
where_RB
the_DT
highest_JJ
Our_FPP1
decision_NN
in_PIN
January_NN
2004_CD
to_PIN
We_FPP1
match_VPRT
the_DT
amount_NN
of_PIN
money_NN
raised_VBD
ethical_JJ
standards_NN
are_VPRT [PASS]
applied_VBN
._.
close_RB
the_DT
UK_NN
research_NN
operations_NOMZ
by_PIN
an_DT
employee_NN
or_CC
group_NN
of_PIN
employees_NN
A_DT
major_JJ
question_NOMZ
facing_VBG [WZPRES]
vaccine_NN
following_VBG [WZPRES]
a_DT
portfolio_NN
and_CC
operational_JJ
for_PIN
their_TPP3
chosen_VBN
charity_NOMZ
._.
In_PIN
2003_CD
,_,
we_FPP1
developers_NN
and_PHC
drug_NN
manufacturers_NN
review_NN
was_VBD [BEMA]
a_DT
difficult_JJ
one_CD
to_TO
take_VB
,_,
introduced_VBD
a_DT
Payroll_NN
Giving_GER
Scheme_NN
in_PIN
the_DT
today_TIME
is_VPRT
how_RB
to_TO
make_VB
the_DT
products_NN
particularly_RB
in_PIN
making_VBG
40_CD
employees_NN
UK_NN
to_TO
enable_VB
employees_NN
to_TO
donate_VB
to_PIN
the_DT
available_JJ
to_PIN
the_DT
areas_NN
of_PIN
the_DT
world_NN
redundant_NN
._.
The_DT
decision_NN
was_VBD [PASS]
driven_VBN
charities_NOMZ
of_PIN
their_TPP3
choice_NN
through_PIN
payroll_NN
,_,
where_RB
they_TPP3
are_VPRT [SPAU] [PASS]
most_EMPH
needed_VBN
,_,
even_RB
by_PIN
specific_JJ
operational_JJ
business_NOMZ
needs_NN
._.
which_WDT [SERE]
has_VPRT
tax_NN
benefits_NN
for_PIN
charities_NOMZ
._.
if_COND
those_DEMO
people_NN
are_VPRT [BEMA]
unable_PRED
to_TO
afford_VB
We_FPP1
aimed_VBN
to_TO
be_VB
as_IN
fair_JJ
as_IN
possible_JJ
with_PIN
Occasionally_RB
,_,
we_FPP1
make_VPRT
donations_NOMZ
to_TO
to_TO
buy_VB
the_DT
product_NN
themselves_TPP3
._.
the_DT
employees_NN
affected_VBN
and_PHC
ran_VBD
a_DT
full_JJ
charities_NOMZ
that_TSUB
support_VPRT
the_DT
communities_NOMZ
We_FPP1
want_VPRT
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
our_FPP1
vaccines_NN
are_VPRT [BEMA]
30-day_JJ
consultation_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
their_TPP3
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
._.
Charitable_JJ
made_VBN
as_IN
widely_RB
available_JJ
as_IN
possible_JJ
._.
views_NN
were_VBD [PASS]
represented_VBN
in_PIN
the_DT
process_NN
._.
To_TO
achieve_VB
this_DEMP
,_,
we_FPP1
aim_VPRT
to_TO
work_VB
with_PIN
We_FPP1
have_VPRT [PEAS]
hosted_VBN
a_DT
number_NN
of_PIN
site_NN
supranational_JJ
organizations_NOMZ
such_JJ
as_IN
HEALTH_NN
AND_PHC
SAFETY_NN
visits_NN
by_PIN
university_NOMZ
students_NN
wanting_VBG [WZPRES]
the_DT
World_NN
Health_NN
Organization_NOMZ
WHO_WP [WHOBJ]
We_FPP1
have_VPRT
an_DT
excellent_JJ
safety_NN
record_NN
to_TO
discover_VB [PRIV]
more_EMPH
about_IN
biotechnology_NN
and_CC
the_DT
Bill_NN
&_CC
Melinda_NN
Gates_NN
Foundation_NOMZ
,_,
and_ANDC
,_,
to_PIN
date_NN
,_,
have_VPRT [SPAU] [PEAS]
never_RB
been_VBN [PASS]
required_VBN [SUAV]
and_PHC
learn_VPRT [PRIV]
from_PIN
Acambis_NN
experiences_NN
._.
both_DT
of_PIN
which_WDT [PIRE]
facilitate_VPRT
the_DT
process_NN
to_TO
report_VB [PUBV]
an_DT
accident_NN
to_PIN
the_DT
Health_NN
For_PIN
the_DT
last_JJ
two_CD
years_NN
,_,
we_FPP1
have_VPRT
also_RB
of_PIN
making_VBG
vaccines_NN
available_JJ
in_PIN
and_CC
Safety_NN
Executive_NN
in_PIN
the_DT
UK_NN
or_CC
sponsored_VBN
the_DT
Biobusiness_NOMZ
:_:
an_DT
insight_NN
endemic_JJ
regions_NN
._.
the_DT
Operational_NN
Health_NN
and_PHC
Safety_NN
into_PIN
bioscience_NN
event_NN
organised_VBN [WZPAST]
by_PIN
the_DT
Administration_NOMZ
in_PIN
the_DT
US_FPP1
._.
As_IN
many_QUAN
Careers_NN
Research_NN
Advisory_NN
Council_NN
._.
of_PIN
our_FPP1
employees_NN
regularly_RB
work_VPRT
in_PIN
a_DT
laboratory_NN
or_CC
manufacturing_GER
setting_GER
,_,
we_FPP1
aim_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
effective_JJ
health_NN
and_PHC
safety_NN
management_NOMZ
is_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
our_FPP1
business_NOMZ
activities_NOMZ
._.
OUR_FPP1
EMPLOYEES_NN
2003_CD
RESEARCH_NN
AND_PHC
DEVELOPMENT_NOMZ
MANUFACTURING_GER
ADMINISTRATION_NOMZ
SALES_NN
AND_PHC
MARKETING_GER
EMPLOYEE_NN
NUMBERS_VPRT
AT_PIN
YEAR_NN
ENDINGS_GER
2001-2003_CD
MARKETED_NN
2001 2002 2003_CD
0_CD
50 100 150 200_CD
250 300 350_CD
